2269:HKG
WuXi Biologics (Cayman) Inc
48,20Â HK$
arrow_downward
−0,90%(−0,44) 1 p
16. okt, 16:08:14 GMT +8 · HKD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 2269 põhistatistika genereerimine…
Ava
49,98Â HK$
Kõrge
50,85Â HK$
Madal
45,82Â HK$
Turu kapit.
198,43Â mld
Keskm. maht
30,42Â mln
Maht
55,18Â mln
Hinna ja tulu suhe
34,48
52 näd kõrgeim
58,00Â HK$
52 näd madalaim
28,48Â HK$
Aktsiatulu
1,40Â HK$
Käibivad aktsiad
1,23Â mld
Töötajate arv
15Â tuh
Ava
49,98Â HK$
Kõrge
50,85Â HK$
Madal
45,82Â HK$
Turu kapit.
198,43Â mld
Keskm. maht
30,42Â mln
Maht
55,18Â mln
Hinna ja tulu suhe
34,48
52 näd kõrgeim
58,00Â HK$
52 näd madalaim
28,48Â HK$
Aktsiatulu
1,40Â HK$
Käibivad aktsiad
1,23Â mld
Töötajate arv
15Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Simply Wall Street
·
43 minuti eest
Freshworks (FRSH) Shares Just Moved, So What Is Going On?
KuCoin
·
33 minuti eest
Nasdaq posts its worst weekly decline since June, gold rebounds but faces resistance at 4200
Yahoo Finance
·
14 tunni eest
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
MarketWatch
·
1 päeva eest
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profiil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Teave üksuse WuXi Biologics (Cayman) Inc kohta